I reported previously (Apr 2014) on Israel’s Entera Bio which is testing treatments for disorders in the parathyroid gland, and osteoporosis. Entera Bio has now filed for floating the biotech on NASDAQ to fund Phase II/III trials of its treatment for hypoparathyroidism.
http://www.globes.co.il/en/article-entera-bio-files-for-nasdaq-ipo-1001197354